The father of a university football player who died of a drug overdose is expected to testify on Wednesday on the second day of trial in a lawsuit by the state of Oklahoma accusing the drugmaker Johnson & Johnson of fuelling the U.S. opioid epidemic.
Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.
Johnson & Johnson is set to face trial on Tuesday in a multi-billion dollar lawsuit by the state of Oklahoma accusing the drugmaker of helping fuel the opioid epidemic.
Johnson & Johnson's greed led the drugmaker to use deceptive marketing to create an oversupply of painkillers that fueled the U.S. opioid epidemic, the state of Oklahoma alleged at the start of the first trial to result from lawsuits over the drug crisis.
Missouri is poised this week to become the only U.S. state without access to legal abortions as public health officials may refuse to renew the license of the last clinic in Missouri to perform the procedure, Planned Parenthood said on Tuesday.
(Reuters Health) - Children who suffer adverse experiences like abuse and neglect may be less likely to have mental health problems in adulthood if they play team sports as teenagers, a U.S. study suggests.
Africa could be declared free of endemic "wild" polio early next year if a strain last seen in Nigeria almost three years ago does not resurface, the World Health Organization's Africa director said on Tuesday.
(Reuters Health) - Men who were overweight as teens may be more likely to develop a rare type of heart muscle damage that can cause heart failure than men who maintained a healthy weight during adolescence, a Swedish study suggests.
(Reuters Health) - Skilled nursing facilities in the U.S. often discharge Medicare patients before daily co-payments kick in, according to a new U.S. study that suggests some patients may be sent home for financial reasons before they're medically ready to leave.
BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.
Related Videos
Introducing the all-new Reuters News app
The new Reuters News app is here, redesigned from the ground up to fit your busy life.
